AC
TVTX icon

Amici Capital’s Travere Therapeutics TVTX Stock Holding History

Amici Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-243,930
Closed -$4.62M – 39
2016
Q4 		$4.62M Sell
243,930
-86,100
-26% -$1.76M 1.79% 20
2016
Q3 		$7.39M Sell
330,030
-308,000
-48% -$5.86M 1.93% 15
2016
Q2 		$11.4M Sell
638,030
-280,108
-31% -$4.53M 2.14% 14
2016
Q1 		$12.5M Sell
918,138
-23,992
-3% -$364K 1.49% 22
2015
Q4 		$18.2M Sell
942,130
-143,385
-13% -$2.86M 1.27% 30
2015
Q3 		$22M Sell
1,085,515
-47,185
-4% -$1.4M 1.05% 34
2015
Q2 		$37.5M Sell
1,132,700
-118,000
-9% -$3.23M 1.37% 29
2015
Q1 		$30M Buy
1,250,700
+543,700
+77% +$8.29M 1.08% 38
2014
Q4 		$8.65M Buy
707,000
+212,000
+43% +$2.19M 0.39% 56
2014
Q3 		$4.46M Buy
495,000
+395,000
+395% +$4.65M 0.15% 89
2014
Q2 		$1.17M Buy
+100,000
New +$1.35M 0.04% 119

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Amici Capital's TVTX Position: Q1 2017 in Review

Amici Capital sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 243,930 shares — an estimated $4.62M sold.

Amici Capital first reported a position in TVTX in Q2 2014 and held it in 11 quarters. The position peaked at $37.5M in Q2 2015. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

  • Amici Capital reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Amici Capital sold 243,930 Travere Therapeutics shares in Q1 2017, an estimated $4.62M.
  • Amici Capital first reported a position in Travere Therapeutics in Q2 2014 and held it in 11 quarters.
  • Amici Capital's Travere Therapeutics position peaked at $37.5M in Q2 2015.
  • 114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Amici Capital's 13F filing for Q1 2017.